New drug duo aims to shrink stubborn lymphoma tumors

NCT ID NCT04998669

Recruiting now Disease control Sponsor: Juan P. Alderuccio, MD Source: ClinicalTrials.gov ↗

Summary

This study is testing a new combination of two drugs, loncastuximab tesirine and rituximab, for adults with follicular lymphoma that has returned or not responded to prior treatments. The main goal is to see if this combination can lead to a complete disappearance of detectable cancer. Researchers will measure how well the tumors shrink and monitor side effects in about 100 participants.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Allegheny Health Network
NOT_YET_RECRUITING

Pittsburgh, Pennsylvania, 15212, United States

Contact

Contact Email: •••••@•••••

Contact Email: •••••@•••••
Florida Cancer Specialists and Research Institute
NOT_YET_RECRUITING

Fort Myers, Florida, 33916, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Rutgers Cancer Institute of New Jersey
RECRUITING

New Brunswick, New Jersey, 08901, United States

Contact Email: •••••@•••••

Contact
University of Miami
RECRUITING

Miami, Florida, 33136, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
University of Michigan
RECRUITING

Ann Arbor, Michigan, 48109, United States

Contact Phone: •••-•••-••••

Contact

Conditions

Explore the condition pages connected to this study.

FOLLICULAR LYMPHOMA